​

Soleno Therapeutics (SLNO) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

SLNO Stock Forecast

Soleno Therapeutics (SLNO) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $123.00, with a high of $125.00 and a low of $121.00. This represents a 79.14% increase from the last price of $68.66.

- $30 $60 $90 $120 $150 High: $125 Avg: $123 Low: $121 Last Closed Price: $68.66

SLNO Stock Rating

Soleno Therapeutics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 10 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 10 Strong Sell Sell Hold Buy Strong Buy

SLNO Price Target Upside V Benchmarks

TypeNameUpside
StockSoleno Therapeutics79.14%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts116
Avg Price Target$125.00$125.00$100.67
Last Closing Price$68.66$68.66$68.66
Upside/Downside82.06%82.06%46.62%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 2538---11
Sep, 2537---10
Aug, 2536---9
Jul, 2536---9
Jun, 2535---8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 07, 2025Goldman Sachs$125.00$58.45113.86%82.06%
Jul 11, 2025Brian SkorneyRobert W. Baird$121.00$81.5748.34%76.23%
Mar 28, 2025Debjit ChattopadhyayGuggenheim$81.00$70.2215.35%17.97%
Dec 02, 2024Raghuram SelvarajuH.C. Wainwright$70.00$50.9137.50%1.95%
Oct 01, 2024Dae Gon HaStifel Nicolaus$74.00$50.4946.56%7.78%
Aug 27, 2024Dae GonStifel Nicolaus$59.00$49.0420.31%-14.07%
Aug 27, 2024Leland GershellOppenheimer$65.00$46.7639.01%-5.33%
May 23, 2024Yasmeen RahimiPiper Sandler$93.00$42.42119.24%35.45%
May 09, 2024Brian SkorneyRobert W. Baird$72.00$47.6451.13%4.86%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 07, 2025Goldman SachsBuyinitialise
Aug 18, 2025H.C. WainwrightBuyBuyhold
Aug 07, 2025Cowen & Co.BuyBuyhold
Jun 23, 2025Cowen & Co.Buyinitialise
Mar 28, 2025GuggenheimBuyBuyhold
Mar 27, 2025LaidlawBuyBuyhold
Dec 02, 2024H.C. WainwrightBuyBuyhold
Sep 27, 2024Piper SandlerOverweightOverweighthold
Sep 03, 2024H.C. WainwrightBuyinitialise
Aug 12, 2024OppenheimerOutperformOutperformhold

Financial Forecast

EPS Forecast

$-5 $-1 $3 $7 $11 $15 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-2.36$-4.38----
Avg Forecast$-2.47$-4.22$-2.60$-0.77$2.68$5.91
High Forecast$-2.32$-4.14$-2.05$0.89$4.36$12.24
Low Forecast$-2.86$-4.29$-3.30$-3.00$-1.48$-0.02
Surprise %-4.45%3.79%----

Revenue Forecast

$0 $200M $400M $600M $800M $1B Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast-$5.63M$37.02M$158.76M$336.47M$535.04M
High Forecast-$10.26M$77.63M$289.45M$613.47M$975.51M
Low Forecast-$1.29M$10.84M$36.30M$76.94M$122.34M
Surprise %------

Net Income Forecast

$-200M $-110M $-20M $70M $160M $250M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-38.99M$-175.85M----
Avg Forecast$-38.99M$-69.56M$-44.12M$-28.80M$23.75M$97.47M
High Forecast$-38.18M$-68.34M$-33.84M$14.68M$71.91M$201.78M
Low Forecast$-47.13M$-70.78M$-54.40M$-49.48M$-24.41M$-267.86K
Surprise %-152.81%----

SLNO Forecast FAQ

Is Soleno Therapeutics stock a buy?

Soleno Therapeutics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 10 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Soleno Therapeutics is a favorable investment for most analysts.

What is Soleno Therapeutics's price target?

Soleno Therapeutics's price target, set by 10 Wall Street analysts, averages $123 over the next 12 months. The price target range spans from $121 at the low end to $125 at the high end, suggesting a potential 79.14% change from the previous closing price of $68.66.

How does Soleno Therapeutics stock forecast compare to its benchmarks?

Soleno Therapeutics's stock forecast shows a 79.14% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Soleno Therapeutics over the past three months?

  • October 2025: 27.27% Strong Buy, 72.73% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • September 2025: 30.00% Strong Buy, 70.00% Buy, 0% Hold, 0% Sell, 0% Strong Sell.
  • August 2025: 33.33% Strong Buy, 66.67% Buy, 0% Hold, 0% Sell, 0% Strong Sell.

What is Soleno Therapeutics’s EPS forecast?

Soleno Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.6, marking a -40.64% decrease from the reported $-4.38 in 2024. Estimates for the following years are $-0.77 in 2026, $2.68 in 2027, and $5.91 in 2028.

What is Soleno Therapeutics’s revenue forecast?

Soleno Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $37.02M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $158.76M, followed by $336.47M for 2027, and $535.04M for 2028.

What is Soleno Therapeutics’s net income forecast?

Soleno Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-44.12M, representing a -74.91% decrease from the reported $-176M in 2024. Projections indicate $-28.801M in 2026, $23.75M in 2027, and $97.47M in 2028.